

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

1-63. (canceled)

64. (currently amended) A bispecific antibody comprising four polypeptides, wherein a first and a second of said polypeptides each comprise a heavy chain constant domain and a heavy chain variable domain, and a third and a fourth of said polypeptides are each common light chains that are either identical to each other, or are identical to each other within the complementarity determining regions (CDRs) and have at least 95% sequence identity ~~different~~ to each other outside of the CDRs, wherein said first polypeptide and said third polypeptide form a binding domain that binds a first antigen, and wherein said second polypeptide and said fourth polypeptide form a binding domain that binds a second antigen, and wherein said first polypeptide and said second polypeptide dimerize to form a bispecific antibody.

65. (previously presented) The bispecific antibody of claim 64, wherein the first polypeptide further comprises a first multimerization domain, and the second polypeptide further comprises a second multimerization domain, and wherein the first and second polypeptides dimerize by interaction of the first and second multimerization domains to form a bispecific antibody.

66. (previously presented) The bispecific antibody of claim 65, wherein the multimerization domains of the first and second polypeptide interact at an amino acid side chain protuberance of one of the first and second polypeptides and an amino acid side chain cavity of the other polypeptide.

67. (previously presented) The bispecific antibody of claim 65, further comprising a non-naturally occurring disulfide bond between the first and second polypeptide.

68. (previously presented) The bispecific antibody of claim 67, wherein the multimerization domain is at least a part of a C_H3 domain region of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second polypeptide.

69. (previously presented) A composition comprising the bispecific antibody of claim 64 and a carrier.

70. (new) A bispecific antibody comprising two heteromeric polypeptides and two light chains wherein:

(a) the first heteromeric polypeptide comprises a first heavy variable domain and a first multimerization domain;

(b) the second heteromeric polypeptide comprises a second heavy variable domain and a second multimerization domain; wherein the two light chains have an amino acid sequence identity of at least 95% identity.

71. (new) The bispecific antibody of claim 70, wherein the amino acid sequence identity is 100%.

72. (new) The bispecific antibody of claim 70, wherein the first and second heteromeric polypeptides dimerize by interaction of the first and second multimerization domains to form a bispecific antibody.

73. (new) The bispecific antibody of claim 70, wherein the first multimerization domain has a protuberance and the second multimerization domain has a cavity, wherein the protuberance is positionable in the cavity.

74. (new) The bispecific antibody of claim 70, further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.

75. (new) The bispecific antibody of claim 74, wherein the multimerization domains comprise a part of a C_H3 domain of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second heteromeric polypeptides.

76. (new) A composition comprising the bispecific antibody of claim 70 and a carrier.

77. (new) The bispecific antibody of claim 73 further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.